Literature DB >> 9777951

Specific K-ras2 mutations in human sporadic colorectal adenomas are associated with DNA near-diploid aneuploidy and inhibition of proliferation.

W Giaretti1, A Rapallo, E Geido, A Sciutto, F Merlo, M Risio, F P Rossini.   

Abstract

Recent studies indicate that p21ras proteins mediate their multiple cell functions through interactions with multiple effectors and that the number of new effectors is growing. We recently reported that K-ras2 mutations in human colorectal adenomas were associated with chromosome instability and proliferation changes. In the present study, we extend these previous observations. Hereditary and multiple (n > or = 5) adenomas and adenomas with early cancer were excluded. Dysplasia was moderate in 91 cases and high in 25, and the median adenoma size was 1.5 cm. K-ras2 spectrum analysis was done by sequence-specific oligonucleotide hybridization using nuclear suspensions provided by analysis and sorting of multiparameter flow cytometry. In particular, tissue inflammatory cells were separated for DNA diploid tumors, whereas DNA aneuploid epithelial subclones were analyzed separately. K-ras2 mutations and DNA aneuploidy were both detected in 29 of 116 (25%) cases. DNA aneuploid index was in the near-diploid region in the majority of cases. DNA aneuploidy was strongly associated with G-->C/T transversions. An association was also found between low S-phase values and G-->A transitions. These findings were confirmed using multivariate logistic regression analysis to account for the effects of size, dysplasia, site, type, age, and sex. These data suggest that specific K-ras2 mutations in a subgroup of human sporadic colorectal adenomas play a role in chromosome instability and, contrary to expectations, are associated with inhibition of proliferation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9777951      PMCID: PMC1853049          DOI: 10.1016/S0002-9440(10)65664-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  67 in total

1.  Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression.

Authors:  K Brown; A Buchmann; A Balmain
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

2.  Fractal modeling of pulmonary blood flow heterogeneity.

Authors:  R W Glenny; H T Robertson
Journal:  J Appl Physiol (1985)       Date:  1991-03

Review 3.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

Review 4.  Increasing complexity of Ras signal transduction: involvement of Rho family proteins.

Authors:  R Khosravi-Far; S Campbell; K L Rossman; C J Der
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

5.  Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1.

Authors:  H Aktas; H Cai; G M Cooper
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

6.  Diploid predominance in hereditary nonpolyposis colorectal carcinoma evaluated by flow cytometry.

Authors:  M Kouri; A Laasonen; J P Mecklin; H Järvinen; K Franssila; S Pyrhönen
Journal:  Cancer       Date:  1990-04-15       Impact factor: 6.860

7.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

8.  Atypical mitoses in colorectal adenomas.

Authors:  C A Rubio
Journal:  Pathol Res Pract       Date:  1991-05       Impact factor: 3.250

9.  Tumor progression by DNA flow cytometry in human colorectal cancer.

Authors:  W Giaretti; L Santi
Journal:  Int J Cancer       Date:  1990-04-15       Impact factor: 7.396

Review 10.  Aneuploidy mechanisms in human colorectal preneoplastic lesions and Barrett's esophagus. Is there a role for K-ras and p53 mutations?

Authors:  W Giaretti
Journal:  Anal Cell Pathol       Date:  1997       Impact factor: 2.916

View more
  6 in total

1.  Mutant K-ras2 in serum.

Authors:  H J N Andreyev; R Benamouzig; M Beranek; P Clarke; D Cunningham; A R Norman; W Giaretti; A F P M de Goeij; B J Iacopetta; E Jullian; K Krtolica; J Q Lee; S T Wang; N Lees; F Al-Mulla; O Muller; M Pauly; V Pricolo; A Russo; C Troungos; N Urosevic; R Ward
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

Review 2.  Molecular pathology of well-differentiated thyroid carcinomas.

Authors:  Manuel Sobrinho-Simões; Ana Preto; Ana Sofia Rocha; Patrícia Castro; Valdemar Máximo; Elsa Fonseca; Paula Soares
Journal:  Virchows Arch       Date:  2005-09-28       Impact factor: 4.064

3.  The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target.

Authors:  Lydia Brandl; Nina Kirstein; Jens Neumann; Andrea Sendelhofert; Michael Vieth; Thomas Kirchner; Antje Menssen
Journal:  Med Oncol       Date:  2018-11-20       Impact factor: 3.064

Review 4.  Generation, repair and replication of guanine oxidation products.

Authors:  Katsuhito Kino; Masayo Hirao-Suzuki; Masayuki Morikawa; Akane Sakaga; Hiroshi Miyazawa
Journal:  Genes Environ       Date:  2017-08-01

5.  Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context.

Authors:  Massimiliano Monticone; Emanuela Biollo; Massimo Maffei; Alessandra Donadini; Francesco Romeo; Clelia Tiziana Storlazzi; Walter Giaretti; Patrizio Castagnola
Journal:  Mol Cancer       Date:  2008-12-16       Impact factor: 27.401

6.  Contiguous 2,2,4-triamino-5(2H)-oxazolone obstructs DNA synthesis by DNA polymerases α, β, η, ι, κ, REV1 and Klenow Fragment exo-, but not by DNA polymerase ζ.

Authors:  Masayo Suzuki; Katsuhito Kino; Taishu Kawada; Takanori Oyoshi; Masayuki Morikawa; Takanobu Kobayashi; Hiroshi Miyazawa
Journal:  J Biochem       Date:  2015-10-21       Impact factor: 3.387

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.